Business
Cellares, which last year became the first company to receive the FDA’s new advanced manufacturing technology designation, expects to support clinical production this year and offer commercial-scale manufacturing services in 2027.
FEATURED STORIES
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year. There’s still more work to do.
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Biohaven has suffered a few setbacks in recent months, including an FDA rejection and a missed $150 million benchmark payment, but CEO Vlad Coric looked for the brighter side at JPM, specifically emphasizing a serendipitous discovery that could get the company in the obesity game.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Senior White House adviser Andy Slavitt said the administration is striving to meet its goal of ensuring enough vaccine supply by summer, but acknowledged there could be some hurdles that will prevent that timeline.
A team led by Dr. Decio Eizirik, M.D., Ph.D., Scientific Director for Indiana Biosciences Research Institute Diabetes Center, has taken a step back from the traditional immune system study approach and found potential for treatment and, theoretically, even a cure.
The Series A financing will help fuel Nuvalent’s research and development efforts for a portfolio of innovative small molecule kinase inhibitors for programs in non-small cell lung cancer.
A brief rundown of who’s raking in cash in the biopharma world.
At the annual J.P. Morgan conference, the biotech industry launched its encore to a wildly successful 2020 – virtually. And, as is becoming the common scenario, attendees found both pros and cons to our new (temporary?) reality.
Vir Biotechnology, Eli Lilly and GlaxoSmithKline struck a three-way collaborative deal to evaluate its investigational monoclonal antibody, VIR-7831, in combination with Lilly’s bamlanivimab in low-risk patients with mild to moderate COVID-19.
Findings from a Phase III long-term extension study show a once-daily therapy consisting of relugolix with estradiol and norethindrone acetate leads to clinically meaningful reductions in menstrual pain and non-menstrual pelvic pain over one year in women with endometriosis.
Nirogy Therapeutics, based in Boston, launched with a $16.5 million Series A financing round. The round was co-led by Santé Ventures and Sporos.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 26, 2021.
The “Woogies” at Wugen have been busy these past three years. BioSpace sat down with CEO John McKearn, Ph.D. to find up what his company has been up to.